# Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Renal Function

> **NCT06106126** · NA · UNKNOWN · sponsor: **Fujian Akeylink Biotechnology Co., Ltd.** · enrollment: 32 (estimated)

## Conditions studied

- COVID-19 Pneumonia

## Interventions

- **DRUG:** GST-HG171 Tablets

## Key facts

- **NCT ID:** NCT06106126
- **Lead sponsor:** Fujian Akeylink Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-10
- **Primary completion:** 2024-02-28
- **Final completion:** 2024-03-01
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2023-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06106126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06106126, "Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Renal Function". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06106126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*